Mar. 4 at 8:37 AM
$IBRX The idea of using IL-15 superagonists like Anktiva for MS is gaining traction in research circles, though the "under
$10" stock market is currently focused on two distinct ways of using this technology: boosting the immune system to clear viruses (like EBV) or rebalancing it to stop the attack on myelin.
As of early 2026, here are the companies and "cousin" drugs to Anktiva that are bridging the gap between IL-15 tech and MS:
1. Nektar Therapeutics (
$NKTR )
* The Stock: Usually trades in the
$1-4 range, making it a very accessible entry point for this specific tech.
* The Drug: NKTR-255. While Anktiva is the "star" for bladder cancer, NKTR-255 is a very similar IL-15 receptor agonist.
* The MS Link: Nektar is the leader in "re-engineering" cytokines. While they are currently pushing NKTR-255 in oncology, they are using the same platform for Rezpegaldesleukin (NKTR-358).
* How it works for MS: Unlike Anktiva (which powers up "Killer" cells), this version is engineered to power up T-regulatory (T-reg) cells. These are the "peacekeeper" cells that tell the immune system to stop attacking the brain in MS patients.
2. Xencor, Inc. (
$XNCR )
* The Stock: Historically higher, but has dipped toward the
$10–
$15 range recently.
* The Tech: They use a platform called XmAb to engineer IL-15 "cytokine-Fc fusions."
* The MS Link: They are developing "targeted" cytokines that aim to deliver the "boost" only to specific parts of the immune system. They have active programs in Autoimmune/Inflammatory diseases. Their research focuses on using these molecules to "reset" the immune system in conditions like MS and Lupus.
3. SOTIO Biotech (Private, but worth watching for IPO/Partnerships)
* The Drug: SOT101 (SO-C101).
* The Strategy: This is a direct competitor to Anktiva. It is an IL-15 superagonist currently in Phase 2 trials. While their primary focus is oncology, they have published research on the "bystander effect"—how IL-15 can help the body clear out the specific "bad" B-cells that cause MS relapses.
Why this is the "Next Wave" for MS
The reason researchers are looking at Anktiva-style drugs for MS is the Epstein-Barr Virus (EBV) connection. A 2022 landmark study proved EBV is likely the "trigger" for MS.
* Current MS drugs: Kill B-cells (where EBV hides) but leave the patient's immune system weak.
* The Anktiva Method: Instead of killing the cells, you "supercharge" the Killer T-cells to find and destroy the virus-infected cells specifically. If you kill the virus, you might stop the MS.
Summary Table: IL-15 & Autoimmune Players
| Company | Ticker | Price (Est. 2026) | Focus |
| Nektar | NKTR | ~
$2.00 -
$4.00 | T-reg stimulation for MS/Lupus |
| Xencor | XNCR | ~
$12.00 -
$18.00 | Engineered "XmAb" cytokines |
| ImmunityBio | IBRX | ~
$5.00 -
$9.00 | Anktiva (Evaluating viral/autoimmune) |
> Pro-Tip: If you are watching these stocks, keep an eye on Phase 2 data readouts. In the biotech world, the "Proof of Concept" (showing it actually works in a human MS patient) is what usually sends a
$3 stock to
$15+ overnight.
